These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 8654677)

  • 1. Human and humanized monoclonal antibodies: preclinical studies and clinical experience.
    Ostberg L; Queen C
    Biochem Soc Trans; 1995 Nov; 23(4):1038-43. PubMed ID: 8654677
    [No Abstract]   [Full Text] [Related]  

  • 2. Monoclonal antibodies in the treatment of myelogenous leukemias.
    Scheinberg DA
    Cancer Treat Res; 1993; 64():213-32. PubMed ID: 7680876
    [No Abstract]   [Full Text] [Related]  

  • 3. [Monoclonal antibody therapies for acute leukemia].
    Takeshita A; Ono R
    Rinsho Ketsueki; 2002 May; 43(5):353-6. PubMed ID: 12096485
    [No Abstract]   [Full Text] [Related]  

  • 4. [Monoclonal antibody therapy targeting surface antigens of leukemic cells].
    Meng FY; Fu YB
    Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):441-3. PubMed ID: 15854546
    [No Abstract]   [Full Text] [Related]  

  • 5. [Antibody therapy for acute leukemia].
    Takeshita A
    Nihon Rinsho; 2007 Jan; 65 Suppl 1():408-15. PubMed ID: 17474439
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of CD33 positive refractory acute lymphoblastic leukemia with Mylotarg.
    Cheung KC; Wong LG; Yeung YM
    Leuk Lymphoma; 2008 Mar; 49(3):596-7. PubMed ID: 18297542
    [No Abstract]   [Full Text] [Related]  

  • 7. Successful use of gemtuzumab ozogamicin in a child with relapsed CD33-positive acute lymphoblastic leukaemia.
    Cotter M; Rooney S; O'Marcaigh A; Smith OP
    Br J Haematol; 2003 Aug; 122(4):687-8. PubMed ID: 12899727
    [No Abstract]   [Full Text] [Related]  

  • 8. Antibody-targeted chemotherapy of relapsed AML.
    Mineur P; Lejeune C; Hennaux V; Eten C
    Br J Haematol; 2003 Apr; 121(1):195-6. PubMed ID: 12670356
    [No Abstract]   [Full Text] [Related]  

  • 9. Chimeric and humanized antibodies with specificity for the CD33 antigen.
    Co MS; Avdalovic NM; Caron PC; Avdalovic MV; Scheinberg DA; Queen C
    J Immunol; 1992 Feb; 148(4):1149-54. PubMed ID: 1737932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD33 is expressed on plasma cells of a significant number of myeloma patients, and may represent a therapeutic target.
    Robillard N; Wuillème S; Lodé L; Magrangeas F; Minvielle S; Avet-Loiseau H
    Leukemia; 2005 Nov; 19(11):2021-2. PubMed ID: 16167057
    [No Abstract]   [Full Text] [Related]  

  • 11. FDA approves antibody-directed cytotoxic agent for acute myeloid leukemia.
    Miller JL
    Am J Health Syst Pharm; 2000 Jul; 57(13):1202, 1204. PubMed ID: 10902059
    [No Abstract]   [Full Text] [Related]  

  • 12. Anti-CD33 monoclonal antibody M195 for the therapy of myeloid leukemia.
    Caron PC; Scheinberg DA
    Leuk Lymphoma; 1993; 11 Suppl 2():1-6. PubMed ID: 8124221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gemtuzumab ozogamicin in pediatric CD33-positive acute lymphoblastic leukemia: first clinical experiences and relation with cellular sensitivity to single agent calicheamicin.
    Zwaan CM; Reinhardt D; Jürgens H; Huismans DR; Hählen K; Smith OP; Biondi A; van Wering ER; Feingold J; Kaspers GJ
    Leukemia; 2003 Feb; 17(2):468-70. PubMed ID: 12592351
    [No Abstract]   [Full Text] [Related]  

  • 14. Correlation of CD33 with poorer prognosis in childhood ALL implicates a potential of anti-CD33 frontline therapy.
    Mejstríková E; Kalina T; Trka J; Starý J; Hrusák O
    Leukemia; 2005 Jun; 19(6):1092-4. PubMed ID: 15830012
    [No Abstract]   [Full Text] [Related]  

  • 15. Persistence of CD33 expression at relapse in CD33(+) acute myeloid leukaemia patients after receiving Gemtuzumab in the course of the disease.
    Chevallier P; Robillard N; Ayari S; Guillaume T; Delaunay J; Mechinaud F; Avet-Loiseau H; Mohty M; Harousseau JL; Garand R
    Br J Haematol; 2008 Dec; 143(5):744-6. PubMed ID: 19036018
    [No Abstract]   [Full Text] [Related]  

  • 16. Cell surface receptor-targeted therapy of acute myeloid leukemia: a review.
    Frankel AE; Sievers EL; Scheinberg DA
    Cancer Biother Radiopharm; 2000 Oct; 15(5):459-76. PubMed ID: 11155818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ab therapy of AML: native anti-CD33 Ab and drug conjugates.
    Jurcic JG
    Cytotherapy; 2008; 10(1):7-12. PubMed ID: 17917880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ursodiol does not prevent hepatic venoocclusive disease associated with Mylotarg therapy.
    Giles F; Garcia-Manero G; Cortes J; Thomas D; Kantarjian H; Estey E
    Haematologica; 2002 Oct; 87(10):1114-6. PubMed ID: 12368170
    [No Abstract]   [Full Text] [Related]  

  • 19. Successful induction of molecular remission with single-agent anti-CD33 antibody (gemtuzumab ozogamicin) in chemotherapy-refractory relapse of acute myeloid leukaemia post-BMT.
    Swords R; Hayden PJ; Molloy K; Lawlor M; Browne PV; Murphy PT
    Eur J Haematol; 2004 Dec; 73(6):450-1. PubMed ID: 15522070
    [No Abstract]   [Full Text] [Related]  

  • 20. [Monoclonal antibody therapy and laboratory medicine].
    Takeshita A
    Rinsho Byori; 2004 Nov; 52(11):917-23. PubMed ID: 15658471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.